NCT01415531

Brief Summary

The purpose of this study is to assess the efficacy, safety, and tolerability of 8 weeks of therapy with nebivolol in comparison to placebo in younger patients 18 - 54 years of age with stage 1 or stage 2 essential hypertension.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
641

participants targeted

Target at P75+ for phase_4 hypertension

Timeline
Completed

Started Aug 2011

Shorter than P25 for phase_4 hypertension

Geographic Reach
1 country

75 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2011

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

August 10, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 12, 2011

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2012

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2012

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

May 16, 2013

Completed
Last Updated

May 16, 2013

Status Verified

March 1, 2013

Enrollment Period

7 months

First QC Date

August 10, 2011

Results QC Date

March 18, 2013

Last Update Submit

March 18, 2013

Conditions

Keywords

Stage 1Stage 2Hypertension

Outcome Measures

Primary Outcomes (1)

  • Trough Seated Diastolic Blood Pressure (DBP)

    Change from baseline in mean seated trough cuff Diastolic Blood Pressure (DBP) at Week 8 as measured by an Omron device. The primary efficacy analysis was based on the Intent to Treat (ITT) population using a Last Observation Carried Forward (LOCF) approach.

    Change from Baseline to Week 8

Secondary Outcomes (1)

  • Trough Seated Systolic Blood Pressure (SBP)

    Change from Baseline to Week 8

Study Arms (2)

1

EXPERIMENTAL

Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration

Drug: Nebivolol

2

PLACEBO COMPARATOR

Dose-matched placebo

Drug: Placebo

Interventions

Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration

1

Dose-match placebo

2

Eligibility Criteria

Age18 Years - 54 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Male and female outpatients, of age 18 - 54 years
  • Patients diagnosed with stage 1 or stage 2 essential hypertension
  • Normal physical examination findings and electrocardiogram (ECG) results or abnormal findings judged by the Investigator to be not clinically significant

You may not qualify if:

  • Secondary hypertension or severe hypertension
  • History of Type 1 diabetes mellitus
  • A medical contraindication to discontinuing a current antihypertensive therapy
  • Clinically significant respiratory disease that prohibit use of a beta blocker

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (75)

Forest Investigative Site 065

Phoenix, Arizona, 85014, United States

Location

Forest Investigative Site 067

Phoenix, Arizona, 85014, United States

Location

Forest Investigative Site 070

Phoenix, Arizona, 85014, United States

Location

Forest Investigative Site 049

Buena Park, California, 90620, United States

Location

Forest Investigative Site 034

Burbank, California, 91505, United States

Location

Forest Investigative Site 039

Costa Mesa, California, 92626, United States

Location

Forest Investigative Site 024

Fountain Valley, California, 92708, United States

Location

Forest Investigative Site 020

Fresno, California, 93726, United States

Location

Forest Investigative Site 021

Fresno, California, 93726, United States

Location

Forest Investigative Site 040

Greenbrae, California, 94904, United States

Location

Forest Investigative Site 047

La Mesa, California, 91942, United States

Location

Forest Investigative Site 073

Los Angeles, California, 90057, United States

Location

Forest Investigative Site 077

Roseville, California, 95661, United States

Location

Forest Investigative Site 060

San Bernardino, California, 92404, United States

Location

Forest Investigative Site 054

San Francisco, California, 94115, United States

Location

Forest Investigative Site 018

Spring Valley, California, 91978, United States

Location

Forest Investigative Site 028

Denver, Colorado, 80220, United States

Location

Forest Investigative Site 059

Brooksville, Florida, 34601, United States

Location

Forest Investigative Site 033

Fort Lauderdale, Florida, 33306, United States

Location

Forest Investigative Site 006

Hallandale, Florida, 33009, United States

Location

Forest Investigative Site 044

Longwood, Florida, 32779, United States

Location

Forest Investigative Site 001

Miami, Florida, 33014, United States

Location

Forest Investigative Site 012

Miami, Florida, 33014, United States

Location

Forest Investigative Site 032

Miami, Florida, 33014, United States

Location

Forest Investigative Site 055

Miami, Florida, 33014, United States

Location

Forest Investigative Site 045

Oviedo, Florida, 32765, United States

Location

Forest Investigative Site 031

St. Petersburg, Florida, 33709, United States

Location

Forest Investigative Site 009

Atlanta, Georgia, 30084, United States

Location

Forest Investigative Site 007

Chicago, Illinois, 60611, United States

Location

Forest Investigative Site 004

Morton, Illinois, 61550, United States

Location

Forest Investigative Site 072

Evansville, Indiana, 47713, United States

Location

Forest Investigative Site 069

Newburgh, Indiana, 47630, United States

Location

Forest Investigative Site 025

Augusta, Kansas, 67010, United States

Location

Forest Investigative Site 029

Louisville, Kentucky, 40213, United States

Location

Forest Investigative Site 068

Madisonville, Kentucky, 42431, United States

Location

Forest Investigative Site 061

Metairie, Louisiana, 70005, United States

Location

Forest Investigative Site 057

New Orleans, Louisiana, 70119, United States

Location

Forest Investigative Site 058

New Orleans, Louisiana, 70119, United States

Location

Forest Investigative Site 008

Lutherville, Maryland, 21093, United States

Location

Forest Investigative Site 062

Fall River, Massachusetts, 02702, United States

Location

Forest Investigative Site 075

Paw Paw, Michigan, 49079, United States

Location

Forest Investigative Site 019

Brooklyn Center, Minnesota, 55430, United States

Location

Forest Investigative Site 017

Chaska, Minnesota, 55318, United States

Location

Forest Investigative Site 038

Belzoni, Mississippi, 39038, United States

Location

Forest Investigative Site 035

Olive Branch, Mississippi, 38654, United States

Location

Forest Investigative Site 023

Las Vegas, Nevada, 89101, United States

Location

Forest Investigative Site 048

Las Vegas, Nevada, 89101, United States

Location

Forest Investigative Site 052

Las Vegas, Nevada, 89101, United States

Location

Forest Investigative Site 014

Elizabeth, New Jersey, 27609, United States

Location

Forest Investigative Site 051

Trenton, New Jersey, 08611, United States

Location

Forest Investigative Site 003

Asheboro, North Carolina, 27203, United States

Location

Forest Investigative Site 010

Charlotte, North Carolina, 28277, United States

Location

Forest Investigative Site 011

Raleigh, North Carolina, 27609, United States

Location

Forest Investigative Site 016

Raleigh, North Carolina, 27609, United States

Location

Forest Investigative Site 005

Wilmington, North Carolina, 28401, United States

Location

Forest Investigative Site 036

Winston-Salem, North Carolina, 27103, United States

Location

Forest Investigative Site 002

Columbus, Ohio, 43213, United States

Location

Forest Investigative Site 050

Norman, Oklahoma, 73069, United States

Location

Forest Investigative Site 030

Portland, Oregon, 33709, United States

Location

Forest Investigative Site 056

Downingtown, Pennsylvania, 19335, United States

Location

Forest Investigative Site 022

Pelzer, South Carolina, 29669, United States

Location

Forest Investigative Site 053

Beaumont, Texas, 77701, United States

Location

Forest Investigative Site 066

Boerne, Texas, 78006, United States

Location

Forest Investigative Site 076

Corpus Christi, Texas, 78404, United States

Location

Forest Investigative Site 037

Dallas, Texas, 75234, United States

Location

Forest Investigative Site 043

Haltom City, Texas, 84070, United States

Location

Forest Investigative Site 015

Houston, Texas, 77081, United States

Location

Forest Investigative Site 026

Houston, Texas, 77081, United States

Location

Forest Investigative Site 027

Houston, Texas, 77081, United States

Location

Forest Investigative Site 074

Houston, Texas, 77081, United States

Location

Forest Investigative Site 071

Orem, Utah, 84058, United States

Location

Forest Investigative Site 042

Sandy City, Utah, 84070, United States

Location

Forest Investigative Site 063

Norfolk, Virginia, 23502, United States

Location

Forest Investigative Site 064

Norfolk, Virginia, 23502, United States

Location

Forest Investigative Site 046

Port Orchard, Washington, 98366, United States

Location

MeSH Terms

Conditions

Hypertension

Interventions

Nebivolol

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

EthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAminesBenzopyransPyransHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Results Point of Contact

Title
Tatjana Lukic, MD, MSc
Organization
Forest Research Institute

Study Officials

  • Tatjana Lukic, MD, M. Sc.

    Forest Laboratories

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 10, 2011

First Posted

August 12, 2011

Study Start

August 1, 2011

Primary Completion

March 1, 2012

Study Completion

April 1, 2012

Last Updated

May 16, 2013

Results First Posted

May 16, 2013

Record last verified: 2013-03

Locations